openPR Logo
Press release

Europe Lung Cancer Drug Pipeline Analysis

06-30-2017 09:12 AM CET | Health & Medicine

Press release from: PNS Pharma

The most common type of cancer in terms of incidence and mortality rate is Lung cancer. Lung cancer is a disease in which the lining of the cell of the lung tissue has an uncontrollable growth which in turn leads to the formation of tumor. There are two main types of lung cancer; small cell lung cancer which accounts for about 20% and non-small cell lung cancer (NSCLC) that accounts for about 80% of the total lung cancers. The major cause for around 80% of all lung cancers is the use of tobacco. Other causes include excessive usage of asbestos and high exposure to radon gas. In Europe, while around one quarter of cancer patients are more than 70 years old, and are largely affected by colorectal, gastric and prostate cancer, the younger population is observed to be more affected by lung cancer, along with brain and kidney cancer.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Europe-Lung-Cancer-Drug-Pipeline-Analysis

“Europe Lung Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of lung cancer in Europe. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Europe lung cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “Europe Lung Cancer Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes

Number of Lung Cancer Drugs in Pipeline by Clinical Phase:

• Preclinical: 7

• Clinical: 4

• Phase-I: 11

• Phase-I/II: 13

• Phase-II: 56

• Phase-II/III: 3

• Phase-III: 28

• Preregistration:2

• Registered: 1

• Marketed: 13

• Unknown: 1

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Europe Lung Cancer Drug Pipeline Analysis here

News-ID: 603315 • Views: 225

More Releases from PNS Pharma

Global Breast Cancer Drug Market & Clinical Trial Insight 2025
" Global Breast Cancer Drug Market & Clinical Trial Insight 2025" Report Highlights: • Global Breast Cancer Drug Market: US$ 40 Billion Opportunity • Global Breast Cancer Drug Clinical Pipeline: More Than 550 Drugs • Marketed Breast Cancer Drugs: More Than 90 Drugs • Comprehensive Clinical Insight & Patent Information • Drug Trials, Pricing, Dosage, Cancer Prevalence Insight: 130 Graphs/Charts Download Report: http://pnspharma.com/buy-report.php?reporttitle=Global-Breast-Cancer-Drug-Market-%26-Clinical-Trial-Insight-2025 The applied science research has marked tremendous advancements in cutting off the epidemic cancer scenarios all around the
Global Peptide Drug Therapeutics Market Size Will Reach US$ 65 Billion by 2026
“Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026” report highlights: • Global Peptide Therapeutics Market Opportunity: US$ 65 Billion • Peptide Therapeutics Market Opportunity: US$ 22 Billion • Insight Peptide Drugs in Clinical Trials: 807 Peptides Drugs • Clinical & Patent Insight on 197 Marketed Peptides • Peptide Clinical Pipeline Is Dominated by Cyclic Peptides: 46 Peptides • Peptides Clinical Trials Insight by Phase, Indication & Company • Future Peptide Therapeutics Market Outlook Download Report: http://pnspharma.com/buy-report.php?reporttitle=Global-Peptide-Therapeutics-Market--%26-Clinical-Pipeline-Insight-2026 “Global Peptide Therapeutics Market
Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026
The global peptide drug market is expected to surpass US$ 50 Billion by 2026 as per recent report "Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026" published by PNS Pharma. Report gives comprehensive insight on ongoing clinical trials of more than 800 peptide drugs across the globe. Report has more than 140 graphs and charts to represent peptide clinical trials data, available drug dosage, price insight and patent
Global Cancer Vaccine Market & Clinical Trial Insight 2025
Recent published report “Global Cancer Vaccine Market & Clinical Trial Insight 2025“ by PNS Pharma highlights on going developments in the field of cancer vaccine market research and clinical trials. currently there are more than 15 cancer vaccines commercially available in the market and close to 370 are in clinical Trial or pipeline. Most of the vaccines in development phases are for the treatment of Breast cancer and

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning